Payment overview · 2025
General Payments
$4,164.82
229 reported records · 18 companies
Healthcare provider profile · identity verified
Bikramjit S Ahluwalia, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · APPLE VALLEY, CA · NPI 1669402467
Verified facts
What the public records show
CMS Open Payments records show Bikramjit S Ahluwalia, MD received $4,164.82 in general payments during 2025 across 229 reported records.
ABBVIE INC. accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Benlysta, Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Orencia, Otezla, Ozempic, Rinvoq, Rybelsus, Saphnelo, Xeljanz.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 430 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Enbrel by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SAPHNELO as an associated drug or biological on 16430 records involving 3390 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Saphnelo by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 277 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORENCIA as an associated drug or biological on 10404 records involving 2463 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Orencia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Benlysta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SIMPONI as an associated drug or biological on 23185 records involving 7011 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Simponi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SIMPONI ARIA as an associated drug or biological on 28612 records involving 8458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Simponi Aria by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 277 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XELJANZ as an associated drug or biological on 32588 records involving 8614 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xeljanz by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $957.29 | 23.0% | 63 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $589.63 | 14.2% | 23 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $518.25 | 12.4% | 21 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $492.92 | 11.8% | 25 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $291.55 | 7.0% | 20 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $270.71 | 6.5% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $198.27 | 4.8% | 11 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $146.38 | 3.5% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $136.74 | 3.3% | 10 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $110.83 | 2.7% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $95.06 | 2.3% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.45 | 2.0% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $76.86 | 1.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.43 | 1.8% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $49.38 | 1.2% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $38.75 | 0.9% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $18.71 | 0.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.61 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,164.82 | 229 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $589.63 | 23 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $587.22 | 42 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $337.68 | 18 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $291.55 | 20 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $270.71 | 17 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $261.51 | 13 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $242.74 | 8 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $212.36 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $147.64 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $146.38 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $141.59 | 3 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $110.83 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $108.89 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $108.89 | 6 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $104.40 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $89.78 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $89.38 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $88.18 | 6 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $76.86 | 4 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $74.17 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $54.52 | 4 | 2025 |
Source payment records
|
|||||
| SPEVIGO Normalized: spevigo |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.54 | 2 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $50.10 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $49.38 | 3 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $40.02 | 3 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $38.75 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $37.23 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.91 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $33.66 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.39 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.88 | 2 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $8.54 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $8.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 277 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 124 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 69 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ORENCIA orencia |
2025 | Orencia | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 189 | exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 430 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SAPHNELO saphnelo |
2025 | Saphnelo | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XELJANZ xeljanz |
2025 | Xeljanz | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
430 | 68 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
54 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SAPHNELO open payments reported associated product |
CMS Open Payments — General Payments 16430 supporting records · 3390 recipient NPIs · example record 1206131348 |
Saphnelo · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
69 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 31 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
277 | 83 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ORENCIA open payments reported associated product |
CMS Open Payments — General Payments 10404 supporting records · 2463 recipient NPIs · example record 1184378623 |
Orencia · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | SIMPONI open payments reported associated product |
CMS Open Payments — General Payments 23185 supporting records · 7011 recipient NPIs · example record 1174257377 |
Simponi · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | SIMPONI ARIA open payments reported associated product |
CMS Open Payments — General Payments 28612 supporting records · 8458 recipient NPIs · example record 1174257377 |
Simponi Aria · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
189 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
277 | 83 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XELJANZ open payments reported associated product |
CMS Open Payments — General Payments 32588 supporting records · 8614 recipient NPIs · example record 1228794176 |
Xeljanz · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 1328 | 297 |
| Methotrexate | Methotrexate Sodium | 1316 | 263 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1045 | 329 |
| Gabapentin | Gabapentin | 732 | 165 |
| Lisinopril | Lisinopril | 558 | 166 |
| Levothyroxine Sodium | Levothyroxine Sodium | 551 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 530 | 151 |
| Leflunomide | Leflunomide | 496 | 122 |
| Omeprazole | Omeprazole | 464 | 119 |
| Rinvoq | Upadacitinib | 430 | 68 |
| Metformin Hcl | Metformin Hcl | 426 | 128 |
| Prednisone | Prednisone | 417 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 391 | 110 |
| Humira(Cf) Pen | Adalimumab | 377 | 46 |
| Losartan Potassium | Losartan Potassium | 357 | 119 |
| Metoprolol Tartrate | Metoprolol Tartrate | 305 | 114 |
| Sulfasalazine | Sulfasalazine | 301 | 69 |
| Alendronate Sodium | Alendronate Sodium | 284 | 78 |
| Eliquis | Apixaban | 277 | 83 |
| Folic Acid | Folic Acid | 271 | 75 |
| Trazodone Hcl | Trazodone Hcl | 270 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 247 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 247 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 237 | 78 |
| Allopurinol | Allopurinol | 236 | 57 |
| Enbrel Sureclick | Etanercept | 232 | 36 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 232 | 60 |
| Furosemide | Furosemide | 229 | 88 |
| Azithromycin | Azithromycin | 212 | 163 |
| Simvastatin | Simvastatin | 209 | 70 |
| Ibuprofen | Ibuprofen | 206 | 72 |
| Pregabalin | Pregabalin | 200 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 193 | 58 |
| Ozempic | Semaglutide | 189 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 50 |
| Atenolol | Atenolol | 166 | 46 |
| Potassium Chloride | Potassium Chloride | 154 | 49 |
| Baclofen | Baclofen | 153 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 149 | 50 |
| Carvedilol | Carvedilol | 124 | 43 |
| Jardiance | Empagliflozin | 124 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 115 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 113 | 27 |
| Glipizide | Glipizide | 112 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 111 | 29 |
| Enalapril Maleate | Enalapril Maleate | 109 | 25 |
| Orencia Clickject | Abatacept | 109 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 107 | 24 |
| Meloxicam | Meloxicam | 106 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 102 | 26 |
| Buspirone Hcl | Buspirone Hcl | 100 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 100 | 66 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 98 | 26 |
| Sertraline Hcl | Sertraline Hcl | 97 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 42 |
| Montelukast Sodium | Montelukast Sodium | 93 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 34 |
| Nifedipine Er | Nifedipine | 90 | 29 |
| Famotidine | Famotidine | 88 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 87 | 45 |
| Clonidine Hcl | Clonidine Hcl | 86 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 30 |
| Donepezil Hcl | Donepezil Hcl | 78 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 76 | 62 |
| Diclofenac Sodium | Diclofenac Sodium | 76 | 31 |
| Benazepril Hcl | Benazepril Hcl | 75 | 23 |
| Methylprednisolone | Methylprednisolone | 74 | 56 |
| Lidocaine | Lidocaine | 72 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 72 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | 13 |
| Simponi | Golimumab | 70 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 69 | 19 |
| Kerendia | Finerenone | 69 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 22 |
| Tramadol Hcl | Tramadol Hcl | 68 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 63 | suppressed |
| Colchicine | Colchicine | 62 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 61 | 18 |
| Xarelto | Rivaroxaban | 60 | 15 |
| Meclizine Hcl | Meclizine Hcl | 59 | 24 |
| Sucralfate | Sucralfate | 59 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 26 |
| Saphnelo | Anifrolumab-Fnia | 56 | suppressed |
| Prolia | Denosumab | 54 | 35 |
| Xeljanz Xr | Tofacitinib Citrate | 54 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 52 | 42 |
| Celecoxib | Celecoxib | 50 | suppressed |
| Glimepiride | Glimepiride | 50 | 14 |
| Ezetimibe | Ezetimibe | 49 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 24 |
| Benlysta | Belimumab | 47 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 47 | 15 |
| Lovastatin | Lovastatin | 46 | 15 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Rybelsus | Semaglutide | 43 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 42 | suppressed |
| Kevzara | Sarilumab | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 12 |
| Repatha Sureclick | Evolocumab | 40 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 39 | 15 |
| Alprazolam | Alprazolam | 38 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 37 |
| Digoxin | Digoxin | 38 | suppressed |
| Naproxen | Naproxen | 38 | 15 |
| Droplet Pen Needle | Pen Needle, Diabetic | 37 | suppressed |
| Temazepam | Temazepam | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Trulicity | Dulaglutide | 36 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 35 | 13 |
| Lactulose | Lactulose | 34 | 13 |
| Levofloxacin | Levofloxacin | 34 | 33 |
| Steglatro | Ertugliflozin Pidolate | 34 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Finasteride | Finasteride | 32 | 13 |
| Humalog | Insulin Lispro | 31 | 15 |
| Acyclovir | Acyclovir | 30 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | 11 |
| Methocarbamol | Methocarbamol | 29 | 15 |
| Nitroglycerin | Nitroglycerin | 29 | 13 |
| Azathioprine | Azathioprine | 28 | suppressed |
| Cimzia (2 Pack) | Certolizumab Pegol | 28 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 24 |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | 19 |
| Lorazepam | Lorazepam | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | 11 |
| Valsartan | Valsartan | 25 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 24 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | 11 |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Epinephrine | Epinephrine | 21 | 17 |
| Lyrica | Pregabalin | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 19 |
| Orencia | Abatacept | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Movantik | Naloxegol Oxalate | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Skyrizi Pen | Risankizumab-Rzaa | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 19 | suppressed |
| Enbrel | Etanercept | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 16 |
| Risperidone | Risperidone | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Cosentyx Unoready Pen | Secukinumab | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Taltz Autoinjector | Ixekizumab | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Ofloxacin | Ofloxacin | 16 | 14 |
| Sulfasalazine Dr | Sulfasalazine | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Simponi Aria | Golimumab | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Xeljanz | Tofacitinib Citrate | 15 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Isoniazid | Isoniazid | 14 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 13 |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | 11 |
| Otezla | Apremilast | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Tradjenta | Linagliptin | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,164.82 · 229 records | ABBVIE INC. | ACTHAR, AIRSUPRA, BENLYSTA, BREZTRI, Bimzelx, COSENTYX, ELIQUIS, EVENITY, FARXIGA, GLASSIA, JARDIANCE, KRYSTEXXA, Kerendia, LUPKYNIS, MOUNJARO, NUCALA, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), ORENCIA, OTEZLA, Ozempic, PANZYGA, PURIFIED CORTROPHIN GEL, QULIPTA, RINVOQ, Rybelsus, SAPHNELO, SKYRIZI, SPEVIGO, TALTZ, TAVNEOS, TONMYA, TREMFYA, UBRELVY, Wegovy, XELJANZ, ZAVZPRET | 26 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Benlysta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error